CORT108297
Phase 2Small molecule
CORT108297 is one of 5 small molecule programs targeting Post-Traumatic Stress Disorder, PTSD. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Post-Traumatic Stress Disorder, PTSD
#DrugCompanyPhaseTrials
1Ritalin
NovartisApproved
Inderal
WWyeth-Lederle Vaccines
Phase 3
Mifeprex
DDanco
Phase 2
Psilocybin
COMPASS PathwaysPhase 2
CORT108297
VVA Office of Research and Development
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CORT108297. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details